GROGENESIS INC (OTCMKTS:GROG) is a well-known name in the field of manufacturing and development of products responsible for plant health enhancement. As per the reports, the company has just released the initial data received from various preliminary field trials that took place in South Australia.

Road So Far:

Grogenesis has been trying hard for a couple of years to get things done in an effective way. It approached a consultant in Australia back in 2014 to arrange an initial trial with an objective get more clarity on the effects the AgraBurst put. The company wanted to study all the effects that AgraBurst would have on the regional high-value crops.

As a result of efforts put in by the company, it was allocated a five hectare portion of a wheat field that was spread across 71.59 hectare land. Grogenesis could use this small portion of land to demonstrate the efficacy of its flagship product. The company was permitted to carry out certain experiments that were allowed by the regional authorities.

Even though, things didn’t turn out as per the expectations during the trial. Reports claim that weather conditions during the entire time were less than what would be the ideal conditions to carry out the trials. Major part of the wheat field performed below the expectations due to the poor weather conditions; hence, much of the wheat crop was reduced to animal fodder.

However the aerial yield mapping procedure of the wheat trial and the nearby area was performed before the harvest. The initial results showed a 5 hectare strip that outperformed in an effective way to all the areas under cultivation. As per the reports, this 5 hectare strip was the only field where AgraBurst was used. The end results showed that it was the only area that came over from the poor growing conditions and showed better results than the rest of the land.

Previous articleSannabis of Newcastle Investment Corp. (NYSE:NCT) Announces Its Plans To Carry Out Hemp Biomass Production in Colombia
Next articleAmbassador Ned L. Siegel Becomes The New Chairman of The Board of Medbox Inc (OTCMKTS:MDBX)
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.